Company: SCLXW
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0000950170-25-071914
Chunk: 26

Company: Scilex Holding Co
Filing Date: 2025-05-15
Form: 424B3
Chunk 26
---
 an amount required for the Company to receive its share of the Canadian Net Revenue on a quarterly basis.

Pursuant to the Elyxyb License Agreement, the Licensee shall obtain and maintain regulatory approval for the Elyxyb Product outside of the United States in accordance with its own business judgment and in its sole and absolute discretion.

Promptly after the Elyxyb Effective Date, the Company is required to (i) facilitate an introduction between the Licensee and CPL as of the Elyxyb Effective Date, and (ii) use reasonable efforts to cause CPL to accept a direct engagement with the Licensee for the manufacturing or supply of the Elyxyb Product in finished dosage form. In addition, the Company agreed to appoint the Licensee as its exclusive distributor of the Elyxyb Product in the entire world other than the United States during the Elyxyb License Term.

The term of the Elyxyb License Agreement commences on the Elyxyb Effective Date and continues until expiration of the last to expire Licensed Patents (as defined therein), unless earlier terminated (the “Elyxyb License Term”).

4. Fair Value Measurements

The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands):

<div align='center'>13</div>

|                                          |     | March 31, 2025 |        |     |               |   |     |                  |   |     |                                           |        |
|:-----------------------------------------|:----|:---------------|-------:|:----|:--------------|:--|:----|:-----------------|:--|:----|:------------------------------------------|-------:|
|                                          |     | Balance        |        |     | Quoted Prices 
 in Active     
 Markets       
 (Level 1)     |   |     | Significant      
 Other            
 Observable       
 Inputs (Level 2) |   |     | Significant Unobservable Inputs (Level 3) |        |
| Liabilities                              |     |                |        |     |               |   |     |                  |   |     |                                           |        |
| Oramed Note                              |     | $              | 14,962 |     | $             | — |     | $                | — |     | $                                         | 14,962 |
| Tranche B Notes                          |     |                | 24,480 |     |               | — |